Results from a phase 3 study showed that galcanezumab-gnlm (Emgality, Eli Lilly) significantly improved work productivity and health and well-being between migraine attacks.
Headache and Migraine
Officials with the FDA have approved celecoxib oral solution 25 mg/mL (Elyxyb, Dr. Reddy’s Laboratories) for the acute treatment of migraine with or without aura in adults.
On December 23, 2019, the FDA approved ubrogepant for the acute treatment of migraine with and without aura in adult patients.
Eptinezumab-jjmr (Vyepti, Lundbeck) decreased mean monthly migraine days in adult patients in 2 phase 3 clinical trials.
Eli Lilly’s lasmiditan (Reyvow) C-V 50 mg and 100 mg for the acute treatment of migraine is now available for prescription.
Allergan’s positive phase 3 trial results indicate a potential use for the CGRP receptor agonist.
From medications to novel treatment methods, a guide to helping your migraine patients.
Currently under DEA review.